CL Stock Analysis — Colgate-Palmolive
Sector: Consumer staples
AI Verdict
Colgate-Palmolive trades at 23.4x next year's earnings, which is only cheap if the forecasted 57.4% EPS surge actually comes through—otherwise, you’re paying up for a narrative that could evaporate quickly despite the brand moat.
Competitive Moat
Colgate-Palmolive dominates oral care globally with entrenched brands and distribution networks that keep competitors at bay. Its scale in manufacturing and shelf space control in emerging markets make its position hard to dislodge.
Summary
Colgate-Palmolive is notable right now for a projected 57.4% jump in earnings next year, a rare acceleration for a mature staples giant.
Where It Stands
Up just 3.14% over the past year, CL trades at 23.4x next year's earnings—just above the sector median of 20x—while its RSI of 64.8 signals shares are approaching overbought territory.
Key Metrics
- RSI: 64.8 — Near Overbought
- Trailing P/E: 36.9x
- Forward P/E: 23.4x
- PEG Ratio: 0.64
- Earnings Growth: +0.6%
- Revenue Growth: +0.0%
- Market Cap: $76.0B
- Dividend Yield: 0.02%
- 1-Year Return: 3.14%
- 52-Week High: $99.33
- 52-Week Low: $74.55
Analyst Consensus
20 Buy · 10 Hold · 1 Sell (31 analysts)
Bull Case
With analysts forecasting 57.4% EPS growth and a forward P/E of 23.4x, you’re paying a modest premium for unusually strong earnings momentum in a defensive sector.
Bear Case
If the forward P/E reverts to the sector median of 20x, the stock could see a roughly 15% valuation pullback from current levels.
Catalyst to Watch
Watch for quarterly earnings—if the 57.4% EPS growth materializes, the premium valuation is justified; if not, expect a reset.